PAJUNK® has been named one of Germany’s 100 fastest-growing medium-sized companies in the 2025 ranking compiled by Munich Strategy in cooperation with the German business newspaper Handelsblatt.
Each year, Munich Strategy evaluates more than 8,000 German mid-sized enterprises from various industries based on their revenue growth, profitability, and overall performance. The resulting list highlights companies that demonstrate above-average growth dynamics and a strong strategic focus.
Being included in this ranking underscores PAJUNK’s continuous development in recent years—driven by consistent investment in innovation, strong international partnerships, and a clear commitment to quality and customer-oriented solutions.
As a family-owned company with 60 years of history in medical technology, PAJUNK has evolved from a small precision-engineering workshop into a global player in regional anesthesia, pain management, neurology, biopsy, and minimally invasive surgery.
This recognition is therefore not only a reflection of business growth but also of the dedication and passion of our employees worldwide—the true foundation of PAJUNK’s success.
As we celebrate our 60th anniversary in 2025, this acknowledgment serves as both a milestone and a motivation to continue driving innovation that empowers care.
Read the full article (in German).